Clinical trials: Stage I Multiple Myeloma
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma, Plasma Cell Neoplasm
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Trial name
- NCT00028600
- Testing
- filgrastim, CD34+ cells, cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
The purpose of this study is to test safety and anti-tumor activity of BT062 in combination with lenalidomide and dexamethasone to define the best doses for treating patients with relapsed and refractory multiple myeloma.
- Trial name
- NCT01638936
- Testing
- BT062 , intravenous administration
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Multiple Myeloma
A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-5421 in patients with multiple myeloma (MM).
- Trial name
- NCT07652281
- Testing
- SHR-5421 for Injection
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Chronic Myeloproliferative Disorders, Infection
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
RATIONALE: Antimicrobial solution comprising trimethoprim-sulfamethoxazole, edetate calcium disodium, and ethanol may help prevent blockages and infections from forming in patients with central venous access catheters or…
- Conditions
- Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma
- Trial name
- NCT01101412
- Testing
- Edetate Calcium Disodium, Ethanol, Trimethoprim-sulfamethoxazole
- Sponsor
- M.D. Anderson Cancer Center
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Trial name
- NCT00112879
- Testing
- arsenic trioxide, ascorbic acid, dexamethasone
- Where
- United States
- Sponsor
- The Cleveland Clinic
Relapsed or Refractory Multiple Myeloma
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
The purpose of this study is to characterize the safety of QLS32015 injection and to determine the recommended Phase 2 dose (RP2D) and to further evaluate the efficacy and safety of QLS32015 injection in participants with…
- Trial name
- NCT05920876
- Testing
- QLS32015
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00052884
- Testing
- filgrastim, amifostine trihydrate, melphalan
- Where
- 16 sites in United States
- Volunteers
- 8 people
- Sponsor
- Eastern Cooperative Oncology Group
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining bone marrow or peripheral stem cell transplantation with chemotherapy may allow the doctor to give…
- Trial name
- NCT00002599
- Testing
- filgrastim, recombinant interferon alfa, sargramostim
- Where
- United Kingdom
- Volunteers
- 750 people
- Sponsor
- Medical Research Council
Multiple Myeloma
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma
Multiple Myeloma (MM) is a morbid disease associated with a poor outcome and while current therapies with new drugs have improved survival, MM still remains incurable in most patients.
- Trial name
- NCT03441958
- Testing
- ECT-001 (UM171) expanded cord blood
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Lymphoma, Myeloma
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL that has come back or has not gone away after treatment.
- Conditions
- Lymphoma, Myeloma, Leukemia
- Trial name
- CHARKALL (NCT00881920)
- Testing
- Kappa CD28 T cells
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Baylor College of Medicine
Extramedullary Multiple Myeloma
A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma
This study is a single-center, open Phase I study, to observe the effectiveness and safety of CT103A combined with different doses of Selinexor in patients with relapsed/refractory extramedullary multiple myeloma, and the…
- Trial name
- NCT05201118
- Testing
- Selinexor, CT103A
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chunrui Li
Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
This phase I/II trial studies the side effects and best dose of ixazomib and to see how well it works when given together with pomalidomide and dexamethasone in treating patients with relapsed or relapsed/refractory multiple…
- Trial name
- NCT02119468
- Testing
- ixazomib citrate, dexamethasone, pomalidomide
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma and Plasma Cell Neoplasm
Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma
RATIONALE: Biological therapies, such as antithymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00378768
- Testing
- anti-thymocyte globulin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
PS-341 in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced cancer.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
- Trial name
- NCT00006362
- Testing
- bortezomib
- Where
- 2 sites in United States
- Sponsor
- Mayo Clinic
Multiple Myeloma
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop cancer cells…
- Trial name
- NCT00124579
- Testing
- bortezomib, dexamethasone, thalidomide
- Where
- 127 sites in United States
- Volunteers
- 7 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CS1 cCAR in patients with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT04156269
- Testing
- BCMA-CS1 cCAR T cells
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- iCell Gene Therapeutics
Multiple Myeloma
A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory Multiple Myeloma,however, a subset of patients relapse due to the loss of target in tumor cells.Dual Specificity CD38 and BCMA CAR-T cells…
- Trial name
- NCT03767751
- Testing
- Dual Specificity CD38 and bcma CAR-T Cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital
Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM)
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
The study is designed to evaluate safety, immunogenicity, and preliminary anti-tumor activity of a multi-peptide immunotherapy (BB-MPI-03) at three peptide+adjuvant dose levels.
- Conditions
- Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma (sMM)
- Trial name
- BBMPI03 (NCT02240537)
- Testing
- Sargramostim, BB-MPI-03, Montanide
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Benovus Bio, Inc.
Refractory Multiple Myeloma, Unspecified Adult Solid Tumor, Protocol Specific
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
Drugs used in chemotherapy, such as arsenic trioxide and pamidronate, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00124605
- Testing
- pamidronate disodium, arsenic trioxide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)